Analysts See $-0.25 EPS for CymaBay Therapeutics, Inc. (CBAY)

July 14, 2018 - By Mary Markley

Analysts expect CymaBay Therapeutics, Inc. (NASDAQ:CBAY) to report $-0.25 EPS on August, 9.They anticipate $0.06 EPS change or 19.35 % from last quarter’s $-0.31 EPS. After having $-0.32 EPS previously, CymaBay Therapeutics, Inc.’s analysts see -21.88 % EPS growth. The stock decreased 4.90% or $0.68 during the last trading session, reaching $13.2. About 1.56 million shares traded or 76.71% up from the average. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 171.12% since July 14, 2017 and is uptrending. It has outperformed by 158.55% the S&P500.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Coverage

Among 9 analysts covering CymaBay Therapeutics (NASDAQ:CBAY), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CymaBay Therapeutics had 16 analyst reports since January 24, 2018 according to SRatingsIntel. Roth Capital initiated it with “Buy” rating and $27.0 target in Thursday, January 25 report. On Monday, April 16 the stock rating was maintained by Roth Capital with “Buy”. The rating was maintained by SunTrust with “Buy” on Friday, March 16. The firm has “Buy” rating given on Wednesday, January 24 by H.C. Wainwright. The rating was maintained by Piper Jaffray with “Buy” on Thursday, March 15. Leerink Swann maintained CymaBay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, April 11 with “Buy” rating. The stock has “Buy” rating by Oppenheimer on Wednesday, May 9. The firm has “Buy” rating by Piper Jaffray given on Wednesday, January 31. The firm has “Buy” rating by Oppenheimer given on Wednesday, March 21. The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) earned “Buy” rating by H.C. Wainwright on Wednesday, March 28.

Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $775.75 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The company's product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

More news for CymaBay Therapeutics, Inc. (NASDAQ:CBAY) were recently published by:, which released: “Key events next week – healthcare” on June 21, 2018.‘s article titled: “CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes” and published on June 25, 2018 is yet another important article.

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.